What’s New

Latest News

Behind the Bill
CMS Releases Draft Guidance on Manufacturer Implementation of 2028 Medicare Drug Price Negotiation Program
07/17/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has unveiled draft guidance for implementing negotiated Medicare drug prices in 2028, proposing new operational requirements for manufacturers, Medicare Advantage plans, pharmacies, and...
The Centers for Medicare & Medicaid Services (CMS) has unveiled draft guidance for implementing negotiated Medicare drug prices in 2028, proposing new operational requirements for manufacturers, Medicare Advantage plans, pharmacies, and...
The Centers for Medicare &...
07/17/2026
First Report Managed Care
First Report Managed Care
News
Why Protected Administrative Time Matters for Oncology APPs: A Comprehensive APSHO Framework
07/17/2026
Kirra Fedyszyn
As oncology practices continue to expand the role of advanced practice providers (APPs), balancing direct patient care with increasingly complex administrative responsibilities has become a critical workforce issue.
As oncology practices continue to expand the role of advanced practice providers (APPs), balancing direct patient care with increasingly complex administrative responsibilities has become a critical workforce issue.
As oncology practices continue...
07/17/2026
Oncology Learning Network APP Institute
Oncology Learning Network APP Institute
News
APP-Led Benign Hematology Consults Improve Access in Community Oncology, Study Finds
07/16/2026
Grace Taylor, MS, MA
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The...
07/16/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
NREMT logo
News
National Registry Board of Directors Meeting – Public Notice and Call for Public Comment on Proposed Update to the Policy Variance Policy
07/16/2026
The updated name better defines how requests for variances to established certification policies are evaluated.
The updated name better defines how requests for variances to established certification policies are evaluated.
The updated name better defines...
07/16/2026
EMSWorld
EMSWorld
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
Psych Congress Network
News
Clomiphene Citrate Recalled Due to CGMP Deviations
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
Pharmacy Learning Network
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
Oncology

Latest Research

Journal of Clinical Pathways logo
Journal of Clinical Pathways
Building Better Oncology Pathways With Specialty Pharmacy Integration
Vol. 12, Issue 3, Issue July 2026
First Report Managed Care
First Report Managed Care
Congress Shifts Focus as Health Policy Scrutiny Continues
Vol. 23, Issue 2, Issue July 2026

HMP Global Learning Network

Featured Interviews

Edgardo Santos, MD
Videos
When Standard Therapy Is Not Feasible in Stage III Non–Small Cell Lung Cancer
06/30/2026
Edgardo Santos, MD
Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...
Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...
Edgardo Santos, MD, reviews the...
06/30/2026
Oncology
Part 5 panel
Videos
Safety Monitoring in High-Risk CSCC
06/24/2026
Christopher Barker, MD; Krupal Patel, MD, MSc, FRCSC, FACS; John Strasswimmer, MD, PhD, FAAD, FACMS; Deborah J.L. Wong, MD, PhD
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion...
06/24/2026
The Dermatologist
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
Videos
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
06/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape...
06/19/2026
EMSWorld
Bruce Sands
Expert Insights
Bruce Sands, MD, on Results from DUET-CD
05/19/2026
Bruce E. Sands, MD, MS
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of...
05/19/2026
Advances in Inflammatory Bowel Disease Network
pediatric asthma
Videos
Pediatric Video Tutorial: Pediatric Asthma
05/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good,...
05/19/2026
EMSWorld
CTP News Desk Image
Viewpoints
Skin Substitute Reimbursement Changes 2026: MAC Denials, Q Codes, and What’s Next
05/19/2026
Daniel L. Kapp, MD
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his...
05/19/2026
Wounds
CTP News Desk Image
Viewpoint
Operational Observations in a New CTP Regulatory Environment
05/08/2026
Nikki Johnston; Kati Kaushal, DNP, FNP-C, CWS
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these...
05/08/2026
Wounds
Advances in Charcot Neuroarthropathy Surgical Techniques Video
Videos
Advances in Charcot Neuroarthropathy Surgical Techniques Video
05/01/2026
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Kyle Lawton, DPM
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight...
05/01/2026
Podiatry Today
Jonathan Friedberg, MD
Videos
Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma
04/30/2026
Jonathan W. Friedberg, MD, MMSc
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc,...
04/30/2026
Oncology
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use